Yunkang Group Limited (2325.HK)

HKD 7.58

(1.07%)

Market Cap (In HKD)

4.53 Billion

Revenue (In HKD)

891.5 Million

Net Income (In HKD)

-102.25 Million

Avg. Volume

5040.00

Currency
HKD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
6.0-12.3
PE
-
EPS
-
Beta Value
-0.341
ISIN
KYG9889T1067
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
Mr. Yong Zhang
Employee Count
-
Website
https://www.yunkanghealth.com
Ipo Date
2022-05-18
Details
Yunkang Group Limited operates as a medical operation service provider in the People's Republic of China. The company offers diagnostic testing services for medical institution alliances, including setting up or upgrading diagnostic centers, the establishment of standard operating procedures for diagnostic testing, diagnostic consultation and staff training, procurement of equipment, smart internet of things, and logistics assistance. It also provides diagnostic outsourcing services comprising pathology tests; infectious disease diagnostic tests, including hepatitis B virus, tuberculosis, human papilloma virus, EB virus, rabies virus, and nucleic acid tests for respiratory pathogens; genetic reproduction and screening tests; and routine diagnostic tests for chronic kidney, blood, autoimmune, endocrine metabolism, and other diseases. In addition, the company offers diagnostic testing services for financial institutions and insurance companies, including personalized diagnostic testing, medical report consultation, and hospital referral services; information technology, medical logistics, and medical equipment procurement; healthcare technology development; and project investment. It provides its services through independent clinical laboratories and on-site diagnostic centers. Yunkang Group Limited was founded in 2008 and is headquartered in Guangzhou, the People's Republic of China.